Electrophysiological remodeling in heart failure.
Heart failure affects nearly 6 million Americans, with a half-million new cases emerging each year. Whereas up to 50% of heart failure patients die of arrhythmia, the diverse mechanisms underlying heart failure-associated arrhythmia are poorly understood. As a consequence, effectiveness of antiarrhythmic pharmacotherapy remains elusive. Here, we review recent advances in our understanding of heart failure-associated molecular events impacting the electrical function of the myocardium. We approach this from an anatomical standpoint, summarizing recent insights gleaned from pre-clinical models and discussing their relevance to human heart failure.
Wang
Yanggan
Y
Department of Pediatrics, Emory University, Atlanta, GA, USA. yanggan.wang@emory.edu
Hill
Joseph A
JA
D000818:Animals; D016880:Anisotropy; D001145:Arrhythmias, Cardiac / Q000503:physiopathology; D001283:Atrioventricular Node / Q000503:physiopathology; D004594:Electrophysiology / Q000379:methods*; D017629:Gap Junctions; D006321:Heart / Q000503:physiopathology; D006333:Heart Failure / Q000503:physiopathology*; D006801:Humans; D009200:Myocardial Contraction; D009206:Myocardium / Q000473:pathology; D011188:Potassium / Q000737:chemistry; D011689:Purkinje Cells / Q000378:metabolism; D051381:Rats
D011188:Potassium